Thursday, June 24, 2010

Stock Alert for EnteroMedics Inc. Issued by MicroStockProfit announces an investment report featuring EnteroMedics Inc. (ETRM 0.52-0.11-16.77%). The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.
The full report is available at:
EnteroMedics Inc. (ETRM) is a development-stage medical device company focused on the design and development of devices that use neuroblocking technology to treat obesity, its associated co-morbidities and other gastrointestinal disorders. The Company's neuroblocking technology, which it refers to as VBLOC therapy, is designed to intermittently block the vagus nerve using high-frequency, low-energy and electrical impulses. The Company's product under development is the Maestro System, which uses VBLOC therapy to limit the expansion of the stomach, helps control hunger sensations between meals, reduces the frequency and intensity of stomach contractions, and produces a feeling of early and prolonged fullness. As of December 31, 2008, the Company was evaluating the Maestro System in human clinical trials conducted in the United States, Australia, Mexico, Norway and Switzerland. The Company was formerly known as Beta Medical Inc. and changed its name to EnteroMedics Inc. in October 2003.
Message Board Search for ETRM:
In the report, the analyst notes:
"For the three months ended March 31, 2010, the Company reported a net loss of $4.7 million, or $0.11 per share, research and development expenses of $2.4 million and general and administrative expenses of $2.0 million.
"The Company also recently announced updated data from its EMPOWER(TM) study in obesity. The EMPOWER study is a randomized, double-blind, controlled pivotal study designed to evaluate the safety and efficacy of the Maestro System in the treatment of obesity… The review further suggested that weight loss effects were evident in both the treatment and control arms because the control arm of the trial, which was intended to be inactive, apparently provided a low-intensity blocking signal that introduced VBLOC Therapy in human subjects."
To read the entire report visit:

No comments: